Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961847 | 0.83 | EPHX2 (0.50) | EPHX2EPHX1DPP4DPP7DPP8 | |
| SCHEMBL4847465 | 0.82 | CHRM3 (0.43) | EPHX2EPHX1CHRM3 | |
| SCHEMBL4955085 | 0.82 | CHRM3 (0.43) | EPHX2EPHX1CHRM3 | |
| SCHEMBL4053842 | 0.81 | EPHX2 (0.51) | EPHX2EPHX1DPP4DPP7DPP8 | |
| SCHEMBL4757343 | 0.79 | POLB (0.54) | EPHX2CHRM3 | |
| SCHEMBL1565871 | 0.78 | EPHX2 (0.49) | EPHX2EPHX1DPP4DPP7KCNH2 | |
| SCHEMBL4117389 | 0.77 | CHRM3 (0.42) | EPHX2EPHX1CHRM3 | |
| SCHEMBL4847784 | 0.77 | CHRM3 (0.42) | EPHX2EPHX1CHRM3 | |
| SCHEMBL23573338 | 0.76 | EPHX2 (0.72) | EPHX2EPHX1 | |
| SCHEMBL10006938 | 0.75 | SLC6A3 (0.56) | EPHX2EPHX1DPP4DPP7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | EPHX2 1464/4885EPHX1 1387/4885CHRM3 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.